Home » Stocks » PRTK

Paratek Pharmaceuticals, Inc. (PRTK)

Stock Price: $8.01 USD -0.11 (-1.35%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $7.82 -0.19 (-2.37%) Apr 16, 5:41 PM
Market Cap 375.61M
Revenue (ttm) 46.92M
Net Income (ttm) -96.54M
Shares Out 44.17M
EPS (ttm) -2.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $8.01
Previous Close $8.12
Change ($) -0.11
Change (%) -1.35%
Day's Open 8.13
Day's Range 7.86 - 8.26
Day's Volume 249,031
52-Week Range 3.81 - 8.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

6 days ago - Zacks Investment Research

BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...

2 weeks ago - GlobeNewsWire

BOSTON, March 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...

1 month ago - GlobeNewsWire

Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021

1 month ago - GlobeNewsWire

BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

2 months ago - GlobeNewsWire

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

2 months ago - GlobeNewsWire

BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

2 months ago - GlobeNewsWire

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up...

Other stocks mentioned: ARGX, EYPT, GILD, GRCL, INO, LLY, ZLAB
3 months ago - Seeking Alpha

Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc. Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.

3 months ago - GlobeNewsWire

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts i...

Other stocks mentioned: BHC, CHMA
4 months ago - GuruFocus

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

4 months ago - GlobeNewsWire

Nuzyra launch trajectory is top of class compared with other antibiotics. BARDA deal signed late 2019 is worth $285M.

4 months ago - Seeking Alpha

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

5 months ago - GlobeNewsWire

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Paratek (PRTK) delivered earnings and revenue surprises of 24.59% and 14.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving...

5 months ago - GlobeNewsWire

Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial and MDR/X...

5 months ago - GlobeNewsWire

Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance

7 months ago - Seeking Alpha

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...

7 months ago - GlobeNewsWire

BOSTON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav...

7 months ago - GlobeNewsWire

Paratek Pharmaceuticals, Inc.(PRTK) CEO Evan Loh on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.3% in pre-market trading after the company reported Q2 results.

8 months ago - Benzinga

BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

8 months ago - GlobeNewsWire

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

8 months ago - GlobeNewsWire

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

BOSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savin...

10 months ago - GlobeNewsWire

Paratek Plods Along

11 months ago - Seeking Alpha

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.1% in pre-market trading after the company reported Q1 results.

11 months ago - Benzinga

As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals

11 months ago - Zacks Investment Research

Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020 Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020

1 year ago - GlobeNewsWire

Paratek Revenue Ramp-Up Is Underappreciated By The Market And Should Drive Stock Price Gains

1 year ago - Seeking Alpha

Paratek Pharmaceuticals: A Bright 2020 Ahead

1 year ago - Seeking Alpha

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Paratek (PRTK) delivered earnings and revenue surprises of 21.36% and 87.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi...

1 year ago - GlobeNewsWire

Paratek Pharmaceuticals: The Best Bet In A Bad Space

1 year ago - Seeking Alpha

Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

Other stocks mentioned: AM, CLVS, CPE, GGB
1 year ago - Zacks Investment Research

Investors need to pay close attention to Paratek Pharmaceuticals (PRTK) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

When stocks rally almost 40% in a single trading session, it tends to draw some new attention.

1 year ago - 24/7 Wall Street

Some government contracts can make or break companies that supply or offer services to the government.

1 year ago - 24/7 Wall Street

Shares of Paratek Pharmaceuticals Inc. PRTK, -4.84% jumped 42% in premarket trading on Thursday on heavy volume after the company said it was awarded a five-year government contract worth up to $169 mil...

1 year ago - Market Watch

- Total award valued at up to $285 million 

1 year ago - GlobeNewsWire

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, HRTX, LGND ...
1 year ago - Benzinga

BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative ther...

1 year ago - GlobeNewsWire

While trade relations and tax-loss selling are causes for concern, opportunities for short-term and swing traders remain abundant.

Other stocks mentioned: AAU, ABEV, BW, GERN, SYNC
1 year ago - Investopedia

About PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracy... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Evan Loh
Employees
196
Stock Exchange
NASDAQ
Ticker Symbol
PRTK
Full Company Profile

Financial Performance

In 2020, PRTK's revenue was $46.92 million, an increase of 183.63% compared to the previous year's $16.54 million. Losses were -$96.54 million, -25.04% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PRTK stock is "Strong Buy." The 12-month stock price forecast is 20.50, which is an increase of 155.93% from the latest price.

Price Target
$20.50
(155.93% upside)
Analyst Consensus: Strong Buy